Unrelated donor transplantation for acute myelogenous leukemia in first remission

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 7, 2011, Pages 1067-1071

  Bashir, Qaiser ^a   Andersson, Borje S ^a   Fernandez Vina, Marcelo ^a   de Padua Silva, Leandro ^a   Giralt, Sergio ^b   Chiattone, Alexandre ^a   Wei, Wei ^a   Sharma, Manish ^a   Anderlini, Paolo ^a   Shpall, Elizabeth J ^a   Popat, Uday ^a   Rodrigues, Morgani ^c   Champlin, Richard E ^a   de Lima, Marcos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Allogeneic transplant; AML; Leukemia; MDS

Indexed keywords

BUSULFAN; FLUDARABINE; METHOTREXATE DERIVATIVE; MINIMETHOTREXATE; PENTOSTATIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; DONOR; EVENT FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BUSULFAN; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LIVING DONORS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; YOUNG ADULT;

EID: 79958743671     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.11.012     Document Type: Article

References (27)

1. Cassileth P.A., Harrington D.P., Hines J.D., et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 1988, 6:583-587.
2. National Comprehensive Cancer Network Guidelines, V.2. 2010. Accessed: Accessed November 30, 2009. http://www.nccn.org.
3. Cassileth P.A., Harrington D.P., Appelbaum F.R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998, 339:1649-1656.
4. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
5. Ciurea S.O., Andersson B.S. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:523-536.
6. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
7. Russell J.A., Savoie M.L., Balogh A., et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007, 13:814-821.
8. Andersson B.S., de Lima M., Thall P.F., et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 14:672-684.
9. Lazarus H.M., Perez W.S., Klein J.P., et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 2006, 132:755-769.
10. Oliansky D.M., Appelbaum F., Cassileth P.A., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2008, 14:137-180.
11. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
12. Keating M.J., Smith T.L., Gehan E.A., et al. Factors related to length of complete remission in adult acute leukemia. Cancer 1980, 45:2017-2029.
13. Ravandi F., Cortes J., Faderl S., et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to one cycle of high dose cytarabine-based induction chemotherapy. Blood 2010 Oct. 5, [Epub ahead of print].
14. Przepiorka D., Khouri I., Ippoliti C., et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 1999, 24:763-768.
15. Marcos de Lima B.A., Fernadez-Vina M., Giralt S., et al. Prophylaxis of graft-versus-host disease (GVHD) with pentostatin, tacrolimus, and " mini" -methotrexate (MTX): a phase I/II controlled, randomized study in unrelated donor (UD) transplantation. Blood (ASH Annu Meet Abstr) 2007, 110. Abstract 40.
16. Parmar S., Del Lima M., Zou Y., et al. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 2009, 114:2884-2887.
17. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004, 32:28-35.
18. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53.
19. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
20. Jabbour E., Giralt S., Kantarjian H., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115:1899-1905.
21. Ringden O., Labopin M., Ehninger G., et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009, 27:4570-4577.
22. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002, 8:477-485.
23. Andersson B.S., de Lima M., Thall P.F., Madden T., Russell J.A., Champlin R.E. Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Curr Opin Oncol 2009, 21(Suppl 1):S11-S15.
24. Geddes M., Kangarloo S.B., Naveed F., et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008, 14:220-228.
25. Wong R., Giralt S.A., Martin T., et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003, 102:3052-3059.
26. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
27. Tallman M.S., Dewald G.W., Gandham S., et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007, 110:409-417.